AI CEOs Urge Congress to Mandate DNA Screening

According to reporting by The Wall Street Journal, The Wall Street Journal first reported that several prominent AI leaders signed an open letter asking Congress to mandate safeguards for the purchase of synthetic nucleic acids. The open letter hosted at screendna.org and covered by Fortune and Quartz names OpenAI CEO Sam Altman, Anthropic CEO Dario Amodei, Google DeepMind CEO Demis Hassabis, and Microsoft AI lead Mustafa Suleyman among the signatories. Per the letter, which was organized by the Foundation for American Innovation and the Institute for Progress, the authors ask Congress to require companies that sell synthetic DNA and RNA to screen customer orders for hazardous sequences, verify purchaser identities, and retain records of transactions. The letter states, "AI systems are improving rapidly, and alongside incredible benefits to science and medicine, there is a real possibility that the knowledge barriers which have historically prevented bad actors from obtaining biological weapons will meaningfully erode." Multiple outlets, including Fortune, report that gene synthesis companies such as Twist Bioscience and Ansa Biotechnologies are also signatories.

Industry-pattern observations: Nucleic acid synthesis screening functions as a critical control point because sequence-level orders are the operational signal that can indicate misuse. Public reporting and the open letter point to existing voluntary screening by members of the International Gene Synthesis Consortium, but the letter argues that voluntary measures are uneven; Quartz and Fortune document that some major providers already perform screening while others do not. Microsofts technical blog post on biosecurity notes that specialized AI tools for protein design can reveal vulnerabilities in legacy screening heuristics, a point that frames why advocates say standards may need updating.

Editorial analysis: Policymakers, vendors, and the research community have historically balanced openness for scientific progress against safeguards that prevent misuse. Observers following similar regulatory shifts note that moving from voluntary to mandatory screening typically creates compliance costs for vendors, drives demand for standardized automated screening tools, and raises questions about false positives that can slow legitimate research. The proposal to require recordkeeping also intersects with privacy, export-control, and international trade issues because synthetic-material supply chains and customers are often cross-border, as described in media coverage of the letter.

Editorial analysis: Key indicators will include whether members of Congress introduce draft legislation that mirrors the letter's requests; how the International Gene Synthesis Consortium and major suppliers respond publicly; and whether federal agencies produce technical guidance or standards for sequence screening and purchaser verification. Practitioners should also watch for efforts to define lists or algorithms for hazardous sequences, because those definitions determine screening sensitivity and scope. Finally, expect debate over enforcement jurisdiction and interplay with existing export-control regimes, an issue raised in reporting on the letter and in industry commentary.